Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results

Rhea-AI Summary

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will release its fourth quarter and full year 2022 financial results after market close on February 28, 2023. A conference call will follow at 4:30 p.m. E.T. to discuss the financials and provide a corporate update. Investors can access the event via a live webcast on Sarepta's investor relations webpage, with a replay available for one year post-event. The company is a leader in precision genetic medicine, specifically focusing on rare diseases like Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), supported by over 40 active development programs.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full year 2022 financial results after the Nasdaq Global Market closes on Tuesday, February 28, 2023. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2022 financial results and to provide a corporate update.

The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.

About Sarepta Therapeutics

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005391/en/

Investor Contact:

Ian Estepan, 617-274-4052

iestepan@sarepta.com



Media Contact:

Tracy Sorrentino, 617-301-8566

tsorrentino@sarepta.com

Source: Sarepta Therapeutics, Inc.

FAQ

When will Sarepta Therapeutics report its Q4 and full year 2022 financial results?

Sarepta Therapeutics will report its financial results on February 28, 2023, after market close.

What time is the Sarepta conference call for financial results?

The conference call will be held at 4:30 p.m. E.T. on February 28, 2023.

Where can I find the webcast for Sarepta Therapeutics' financial results?

The webcast will be available on Sarepta's investor relations website.

What is Sarepta Therapeutics focused on?

Sarepta Therapeutics focuses on precision genetic medicine for rare diseases, particularly DMD and LGMDs.